New York, NY, August 17, 2013 --(PR.com
)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Charles Loughlin, Partner, Baker Botts LLP will speak at the Knowledge Congress’ webcast entitled: “Pay-for-Delay Antitrust Issues in the Pharmaceutical Industry: Updates and Enforcements in 2013.” This event is scheduled for September 11, 2013 from 12:00pm – 2:00pm (ET).
For further details, please visit:
About Charles Loughlin
Chuck Loughlin is a Partner in Baker Botts' Antitrust and Competition Practice in Washington, D.C. He has extensive experience in litigating antitrust issues in the pharmaceutical industry, and has been involved in "reverse payment" patent settlement cases since the FTC began investigating such settlements in the late 1990s. His experience in this area has included a successful trial and appeal against the FTC, denial of certification of an indirect purchaser class, summary judgment in state court, and an early dismissal from one case altogether. Chuck also has been involved in counseling pharmaceutical companies on "reverse payment" patent settlement issues, and has spoken frequently on the topic.
Chuck has litigated antitrust issues in other industries as well, including recently defeating class certification and obtaining summary judgment on behalf of the country's largest grocery wholesaler. He has worked on a number of commercial litigation and arbitration matters outside the antitrust field, including securities, trademark and false advertising, products liability and white collar crime.
About Baker Botts LLP
Baker Botts is an international law firm with 700 lawyers and a network of 14 offices around the globe. Based on our broad experience and our in-depth knowledge of our clients' industries, we are recognized as a leading firm in the energy, technology and life sciences sectors. Baker Botts has earned the privilege of working on some of the most fascinating and complex legal matters in the world. Throughout our 170-year history, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. www.bakerbotts.com.
The growing number of pay-for-delay settlements in the pharmaceutical industry will continue to be a significant issue surrounding antitrust related matters. Under the pay-for-delay settlements, also known as reverse payment settlements, pharmaceutical patent holders pay generic drug manufacturers to not challenge the patent’s validity in court. The payment also seeks to have the generic manufacturer to delay the market entry of the generic drug. Recognizing the settlement’s impact on competition, the FTC continues to attempt to counter pay for delay settlements by filing antitrust lawsuits for patent infringement and by conducting investigations on its own. However, the courts so far seem to think otherwise as they continue to uphold reverse settlements as lawful and not a violation of antitrust laws.
A panel of thought leaders and experienced practitioners organized by The Knowledge Group will help drug manufacturers, patent attorneys and other interested professionals understand most significant issues involved in pay for delay agreements, including:
- Treatment of Reverse Settlements Under the Sherman Antitrust Act
- Pay-for-Delay Under the Hatch-Waxman Act
- Notable Patent Infringement Cases Relating to Pay-for-Delay and Key Takeaways
- Regulatory Works on the Increasing Use of Pay-for-Delay Settlements
- And so much more.
About The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series
The Knowledge Congress was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: www.knowledgecongress.org.